Key Dates

Related Announcements

• July 21, 2021 - Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional). See NOFO PAR-21-290.

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to extend the expiration date for PAR-21-290, Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional).  Therefore, with the addition/extension by one Application Due Date, PAR-21-290 now expires on January 8, 2025.

The following sections in Part 1. Overview Information, Key Dates section have been changed:  

Currently Reads: 

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date: September 08, 2024.

Modified to Read (in bold italics):

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date: January 08, 2025.

All other aspects of PAR-21-290 remain unchanged.

Inquiries

Please direct all inquiries to:

Chiayeng Wang, Ph.D.
Division of Cancer Diagnosis and Treatment (DCTD)
National Cancer Institute (NCI)
Telephone: 240-276-6624
Email: [email protected]